Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2014

Open Access 01-12-2014 | Research

Association of candidate gene polymorphisms and TGF-beta/IL-10 levels with malaria in three regions of Cameroon: a case–control study

Authors: Tobias O Apinjoh, Judith K Anchang-Kimbi, Clarisse Njua-Yafi, André N Ngwai, Regina N Mugri, Taane G Clark, Kirk A Rockett, Dominic P Kwiatkowski, Eric A Achidi, in collaboration with The MalariaGEN Consortium

Published in: Malaria Journal | Issue 1/2014

Login to get access

Abstract

Background

Plasmodium falciparum malaria is one of the most widespread and deadliest infectious diseases in children under five years in endemic areas. The disease has been a strong force for evolutionary selection in the human genome, and uncovering the critical host genetic factors that confer resistance to the disease would provide clues to the molecular basis of protective immunity and improve vaccine development initiatives.

Methods

The effect of single nucleotide polymorphisms (SNPs) and plasma transforming growth factor beta (TGF-β) and interleukin 10 (IL-10) levels on malaria pathology was investigated in a case–control study of 1862 individuals from two major ethnic groups in three regions with intense perennial P. falciparum transmission in Cameroon. Thirty-four malaria candidate polymorphisms, including the sickle cell trait (HbS), were assayed on the Sequenom iPLEX platform while plasma TGF-β and IL-10 levels were measured by sandwich ELISA.

Results

The study confirms the known protective effect of HbS against severe malaria and also reveals a protective effect of SNPs in the nitrogen oxide synthase 2 (NOS2) gene against malaria infection, anaemia and uncomplicated malaria. Furthermore, ADCY9 rs10775349 (additive G) and ABO rs8176746 AC individuals were associated with protection from hyperpyrexia and hyperparasitaemia, respectively. Meanwhile, individuals with the EMR1 rs373533 GT, EMR1 rs461645 CT and RTN3 rs542998 (additive C) genotypes were more susceptible to hyperpyrexia while both females and males with the rs1050828 and rs1050829 SNPs of G6PD, respectively, were more vulnerable to anaemia. Plasma TGF-β levels were strongly correlated with heterozygosity for the ADCY9 rs2230739 and HBB rs334 SNPs while individuals with the ABO rs8176746 AC genotype had lower IL-10 levels.

Conclusion

Taken together, this study suggests that some rare polymorphisms in candidate genes may have important implications for the susceptibility of Cameroonians to severe malaria. Moreover using the uncomplicated malaria phenotype may permit the identification of novel pathways in the early development of the disease.
Appendix
Available only for authorised users
Literature
1.
2.
MalariaGEN: A global network for investigating the genomic epidemiology of malaria. Nature. 2008, 456: 732-738.CrossRef
3.
4.
Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP: In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet. 2003, 33: 469-475.CrossRefPubMed
5.
Ouma C, Davenport GC, Were T, Otieno MF, Hittner JB, Vulule JM, Martinson J, Ong'echa JM, Ferrell RE, Perkins DJ: Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. Hum Genet. 2008, 124: 515-524.PubMedCentralCrossRefPubMed
6.
Apinjoh TO, Anchang-Kimbi JK, Njua-Yafi C, Mugri RN, Ngwai AN, Rockett KA, Mbunwe E, Besingi RN, Clark TG, Kwiatkowski DP, Achidi EA: Association of cytokine and toll-like receptor gene polymorphisms with severe malaria in three regions of Cameroon. PLoS One. 2013, 8: e81071-PubMedCentralCrossRefPubMed
7.
Williams TN: Human red blood cell polymorphisms and malaria. Curr Opin Microbiol. 2006, 9: 388-394.CrossRefPubMed
8.
Würzner R, Hobart MJ, Fernie BA, Mewar D, Potter PC, Orren A, Lachmann PJ: Molecular basis of subtotal complement C6 deficiency, A carboxy- terminally truncated but functionally active C6. J Clin Investigat. 1995, 95: 1877-1883.CrossRef
9.
van de Vosse E, Ali S, de Visser AW, Surjadi C, Widjaja S, Vollaard AM, van Dissel JT: Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR). Hum Genet. 2005, 118: 138-140.CrossRefPubMed
10.
Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, Zhao LP, McElrath MJ: Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol. 2006, 80: 2463-71.PubMedCentralCrossRefPubMed
11.
Griffiths MJ, Shafi MJ, Popper SJ, Hemingway CA, Kortok MM, Wathen A, Rockett KA, Mott R, Levin M, Newton CR, Marsh K, Relman DA, Kwiatkowski DP: Genomewide analysis of the host response to malaria in Kenyan children. J Infect Dis. 2005, 191: 1599-1611.CrossRefPubMed
12.
Bellamy R, Kwiatkowski D, Hill AV: Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. Trans R Soc Trop Med Hyg. 1998, 92: 312-316.CrossRefPubMed
13.
Newbold C, Warn P, Black G, Berendt A, Craig A, Snow B, Msobo M, Peshu N, Marsh K: Receptor-specific adhesion and clinical disease in Plasmodium falciparum. Am J Trop Med Hyg. 1997, 57: 389-398.PubMed
14.
Kun JF, Mordmuller B, Lell B, Lehman LG, Luckner D, Kremsner PG: Polymorphism in the promoter region of the inducible nitric oxide synthase gene and protection against malaria. Lancet. 1998, 351: 265-266.CrossRefPubMed
15.
Kun JF, Mordmuller B, Perkins DJ, May J, Mercereau-Puijalon O, Alpers M, Weinberg JB, Kremsner PG: Nitric oxide synthase 2(Lambarene) (G-954C), increased nitric oxide production, and protection against malaria. J Infect Dis. 2001, 184: 330-336.CrossRefPubMed
16.
Levesque MC, Hobbs MR, Anstey NM, Vaughn TN, Chancellor JA, Pole A, Perkins DJ, Misukonis MA, Chanock SJ, Granger DL, Weinberg JB: Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. J Infect Dis. 1999, 180: 1994-2002.CrossRefPubMed
17.
Burgner D, Usen S, Rockett K, Jallow M, Ackerman H, Cervino A, Pinder M, Kwiatkowski DP: Nucleotide and haplotypic diversity of the NOS2A promoter region and its relationship to cerebral malaria. Hum Genet. 2003, 112: 379-386.PubMed
18.
Hobbs MR, Udhayakumar V, Levesque MC, Booth J, Roberts JM, Tkachuk AN, Pole A, Coon H, Kariuki S, Nahlen BL, Mwaikambo ED, Lal AL, Granger DL, Anstey NM, Weinberg JB: A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet. 2002, 360: 1468-1475.CrossRefPubMed
19.
Linke A, Kühn R, Müller W, Honarvar N, Li C, Langhorne J: Plasmodium chabaudi chabaudi: differential susceptibility of gene-targeted mice deficient in IL-10 to an erythrocytic-stage infection. Exp Parasitol. 1996, 84: 253-263.CrossRefPubMed
20.
Chelimo K, Sumba PO, Kazura JW, Ofula AV, John CC: Interferon-gamma responses to Plasmodium falciparum liver-stage antigen-1 and merozoite surface protein-1 increase with age in children in a malaria holoendemic area of western Kenya. Malar J. 2003, 2: 37-PubMedCentralCrossRefPubMed
21.
Omer FM, Riley EM: Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med. 1998, 188: 39-48.PubMedCentralCrossRefPubMed
22.
Perkins DJ, Weinberg JB, Kremsner PG: Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. J Infect Dis. 2000, 182: 988-992.CrossRefPubMed
23.
Achidi EA, Apinjoh TO, Yafi CN, Besingi R, Anchang JK, Awah NW, Troye-Blomberg M: Plasma levels of tumour necrosis factor-alpha, interleukin-10, interleukin-12, macrophage inhibition factor and transforming growth factor-beta in children with severe and uncomplicated falciparum malaria. J Trop Dis. 2013, 1: 103-
24.
Carpenter D, Abushama H, Bereczky S, Färnert A, Rooth I, Troye-Blomberg M, Quinnell RJ, Shaw MA: Immunogenetic control of antibody responsiveness in a malaria endemic area. Hum Immunol. 2007, 68: 165-169.CrossRefPubMed
25.
Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, Clark TG, Kivinen K, Bojang KA, Conway DJ, Pinder M, Sirugo G, Sisay-Joof F, Usen S, Auburn S, Bumpstead SJ, Campino S, Coffey A, Dunham A, Fry AE, Green A, Gwilliam R, Hunt SE, Inouye M, Jeffreys AE, Mendy A, Palotie A, Potter S, Ragoussis J, Rogers J, Rowlands K: Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet. 2009, 41: 657-665.PubMedCentralCrossRefPubMed
26.
Toure O, Konate S, Sissoko S, Niangaly A, Barry A, Sall AH, Diarra E, Poudiougou B, Sepulveda N, Campino S, Rockett KA, Clark TG, Thera MA, Doumbo O, Collaboration with The MalariaGEN Consortium: Candidate Polymorphisms and Severe Malaria in a Malian Population. Plos One. 2012, 7: e43987-PubMedCentralCrossRefPubMed
27.
Manjurano A, Clark TG, Nadjm B, Mtove G, Wangai H, Sepulveda N, Campino SG, Maxwell C, Olomi R, Rockett KR, Jeffreys A, MalariaGen C, Riley EM, Reyburn H, Drakeley C: Candidate human genetic polymorphisms and severe malaria in a Tanzanian Population. PLoS One. 2012, 7: e47463-PubMedCentralCrossRefPubMed
28.
Basco LK, Ngane VF, Ndounga M, Same-Ekobo A, Youmba J, Abodo RTO, Soula G: Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. Am J Trop Med Hyg. 2006, 75: 388-395.PubMed
29.
Quakyi IA, Leke RGF, Befidi-Mengue R, Tsafack M, Bomba-Nkolo D, Manga L, Tchinda V, Njeungue E, Kouontchou S, Fogako J, Nyonglema P, Harun LT, Djokam R, Sama G, Eno A, Megnekou R, Metenou S, Ndoutse L, Same-Ekobo A, Alake G, Meli J, Ngu J, Tietche F, Lohoue J, Mvondo JL, Wansi E, Leke R, Folefack A, Bigoga J, Bomba-Nkolo C: The epidemiology of Plasmodium falciparum malaria in two Cameroonian villages: Simbok and Etoa. Am J Trop Med Hyg. 2000, 63: 222-230.PubMed
30.
Manga L, Bouchite B, Toto JC, Froment A: Anopheles species and the transmission of malaria in the forest/savanna transition zone in central Cameroon. Bull Soc Path Exot. 1997, 90: 128-130.
31.
Wanji S, Tanke T, Atanga SN, Ajonina C, Nicolas T, Fontenille D: Anopheles species of the Mount Cameroon region: biting habit, feeding behaviour and entomological inoculation rates. Trop Med Int Health. 2003, 8: 643-649.CrossRefPubMed
32.
Nkuo Akenji TK, Ajame EA, Achidi EA: An investigation of symptomatic malaria parasitaemia and anaemia in nursery and primary school children in Buea District Cameroon. Cen Afr J Med. 2002, 48: 1-4.
33.
Achidi EA, Apinjoh TO, Mbunwe E, Besingi R, Yafi C, Awah NW, Ajua A, Anchang JK: Febrile status, malarial parasitaemia and gastro-intestinal helminthiases in schoolchildren resident at different altitudes, in south–western Cameroon. Ann Trop Med Parasitol. 2008, 102: 103-118.CrossRefPubMed
34.
Bigoga JD, Manga L, Titanji VPK, Coetzee M, Leke RGF: Malaria vectors and transmission dynamics in coastal south-western Cameroon. Malar J. 2007, 6: 5-PubMedCentralCrossRefPubMed
35.
Achidi EA, Apinjoh TO, Anchang-Kimbi JK, Mugri RN, Ngwai AN, Judith K, Anchang-Kimbi JK, Yafi CN: Severe and uncomplicated falciparum malaria in children from three regions and three ethnic groups in Cameroon: prospective study. Malar J. 2012, 11: 215-PubMedCentralCrossRefPubMed
36.
WHO: Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000, 94 (1): S1-S90.CrossRef
37.
Rooth I, Perlmann H, Bjorkman A: Plasmodium falciparum reinfection in children from a holoendemic area in relation to seroreactivities against oligopeptides from different malarial antigens. Am J Trop Med Hyg. 1991, 45: 309-318.PubMed
38.
Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N: Whole genome amplification from a single cell: implications for genetic analysis. Proc Nat Acad Sci USA. 1992, 89: 5847-5851.PubMedCentralCrossRefPubMed
39.
Ross P, Hall L, Smirnov I, Haff L: High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotech. 1998, 16: 1347-1351.CrossRef
40.
Kwiatkowski DP: How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Gen. 2005, 77: 171-192.CrossRef
41.
Teo YY, Fry AE, Clark TG, Tai ES, Seielstad M: On the usage of HWE for identifying genotyping errors. Ann Hum Genet. 2007, 71: 701-704.CrossRefPubMed
42.
43.
Dhangadamajhi G, Mohapatra BN, Kar SK, Ranjit MR: The CCTTT pentanucleotide microsatellite in iNOS promoter influences the clinical outcome in P. falciparum infection. Parasitol Res. 2009, 104: 1315-1320.CrossRefPubMed
44.
Wang SS, Davis S, Cerhan JR, Hartge P, Severson RK, Cozen W, Lan Q, Welch R, Chanock SJ, Rothman N: Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogen. 2006, 27: 1826-1834.
45.
Martin MC, Martinez A, Mendoza JL, Taxonera C, Diaz-Rubio M, Fernandez-Arquero M, de la Concha EG, Urcelay E: Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility. Immunogenet. 2007, 59: 833-837.CrossRef
46.
Toyota T, Hattori E, Meerabux J, Yamada K, Saito K, Shibuya H, Nankai M, Yoshikawa T: Molecular analysis, mutation screening, and association study of adenylate cyclase type 9 gene (ADCY9) in mood disorders. Am J Med Genet. 2002, 114: 84-92.CrossRefPubMed
47.
Baud V, Chissoe SL, Viegas-Pequignot E, Diriong S, N’Guyen VC, Roe BA, Lipinski M: EMR1, an unusual member in the family of hormone receptors with seven transmembrane segments. Genomics. 1995, 26: 334-344.CrossRefPubMed
48.
Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, Yki-Jarvine H: Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metabol. 2008, 295: 85-91.CrossRef
49.
Panda AK, Panda SK, Sahu AN, Tripathy R, Ravindran B, Das BK: Association of ABO blood group with severe falciparum malaria in adults: case control study and meta-analysis. Malar J. 2011, 10: 309-PubMedCentralCrossRefPubMed
50.
Rout R, Dhangadamajhi G, Ghadei M, Mohapatra BN, Kar SK, Ranjit M: Blood group phenotypes A and B are risk factors for cerebral malaria in Odisha, India. Trans R Soc Trop Med Hyg. 2012, 106: 538-543.CrossRefPubMed
51.
Pathirana SL, Alles HK, Bandara S, Phone-Kyaw M, Perera MK, Wickremasinghe AR, Mendis KN, Handunnetti SM: ABO-blood-group types and protection against severe Plasmodium falciparum malaria. Ann Trop Med Parasitol. 2005, 99: 119-124.CrossRefPubMed
52.
Lell B, May J, Schmidt-Ott RJ, Lehman LG, Luckner D, Greve B, Matousek P, Schmid D, Herbich K, Mockenhaupt FP, Meyer CG, Bienzle U, Kremsner PG: The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis. 1999, 28: 794-799.CrossRefPubMed
53.
Harrison T, Samuel BU, Akompong T, Hamm H, Mohandas N, Lomasney JW, Haldar K: Erythrocyte G protein-coupled receptor signaling in malarial infection. Science. 2003, 301: 1734-1736.CrossRefPubMed
54.
Auburn S, Diakite M, Fry AE, Ghansah A, Campino S, Richardson A, Jallow M, Sisay-Joof F, Pinder M, Griffiths MJ, Peshu N, Williams TN, Marsh K, Molyneux ME, Taylor TE, Koram KA, Oduro AR, Rogers WO, Rockett KA, Haldar K, Kwiatkowski DP: Association of the GNAS locus with severe malaria. Hum Genet. 2008, 124: 499-506.PubMedCentralCrossRefPubMed
55.
Silveira H, Ramos S, Abrantes P, Lopes LF, do Rosario VE, Abrahamsen MS: Effect of chloroquine on gene expression of Plasmodium yoelii nigeriensis during its sporogonic development in the mosquito vector. Malar J. 2007, 6: 84-PubMedCentralCrossRefPubMed
Metadata
Title
Association of candidate gene polymorphisms and TGF-beta/IL-10 levels with malaria in three regions of Cameroon: a case–control study
Authors
Tobias O Apinjoh
Judith K Anchang-Kimbi
Clarisse Njua-Yafi
André N Ngwai
Regina N Mugri
Taane G Clark
Kirk A Rockett
Dominic P Kwiatkowski
Eric A Achidi
in collaboration with The MalariaGEN Consortium
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2014
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-13-236

Other articles of this Issue 1/2014

Malaria Journal 1/2014 Go to the issue

Methodology

Label-free microfluidic enrichment of ring-stage Plasmodium falciparum-infected red blood cells using non-inertial hydrodynamic lift

Research

A phase III trial to evaluate the efficacy, fabric integrity and community acceptance of Netprotect® using a recommended long-lasting insecticidal net as positive control

Methodology

Rapid detection of Plasmodium falciparum with isothermal recombinase polymerase amplification and lateral flow analysis

Research

Introducing the concept of a new pre-referral treatment for severely ill febrile children at community level: a sociological approach in Guinea-Bissau

Research

Genetic variation and recurrent parasitaemia in Peruvian Plasmodium vivax populations

Research

Parasite densities modulate susceptibility of mice to cerebral malaria during co-infection with Schistosoma japonicum and Plasmodium berghei
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits